Trial Profile
A Phase 2, Randomized Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Nov 2023
Price :
$35
*
At a glance
- Drugs IONIS FB LRX (Primary)
- Indications Age-related macular degeneration
- Focus Therapeutic Use
- Acronyms GOLDEN
- Sponsors Ionis Pharmaceuticals
- 21 Nov 2023 Planned End Date changed from 1 Jul 2024 to 1 Jun 2024.
- 02 Apr 2023 This trial has been completed in Netherlands according to European Clinical Trials Database record.
- 17 Mar 2023 Planned End Date changed from 1 Jan 2024 to 1 Jul 2024.